Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von Knebel Doeberitz M, Kloor M. Bauer K, et al. Among authors: reuschenbach m. Cancer Immunol Immunother. 2013 Jan;62(1):27-37. doi: 10.1007/s00262-012-1303-8. Epub 2012 Jun 23. Cancer Immunol Immunother. 2013. PMID: 22729559 Free PMC article.
A systematic review of humoral immune responses against tumor antigens.
Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. Reuschenbach M, et al. Cancer Immunol Immunother. 2009 Oct;58(10):1535-44. doi: 10.1007/s00262-009-0733-4. Epub 2009 Jun 28. Cancer Immunol Immunother. 2009. PMID: 19562338 Free PMC article. Review.
Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer.
Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M, Kloor M. Surmann EM, et al. Among authors: reuschenbach m. Cancer Immunol Immunother. 2015 Mar;64(3):357-66. doi: 10.1007/s00262-014-1638-4. Epub 2014 Dec 2. Cancer Immunol Immunother. 2015. PMID: 25445815 Free PMC article.
A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, Sauer M, Al-Batran SE, Kaufmann AM, Schneider A, Jäger E, von Knebel Doeberitz M. Reuschenbach M, et al. Cancer. 2016 May 1;122(9):1425-33. doi: 10.1002/cncr.29925. Epub 2016 Mar 7. Cancer. 2016. PMID: 26949913 Free article. Clinical Trial.
68 results